Skip to main content

Table 1 A summary of in vitro studies on the role of EGCG on AD prevention

From: The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: an overview of pre-clinical studies and translational perspectives in clinical practice

Cell lines

Drug and dosage

Results

References

MC65

EGCG 20 μM

EGCG reduced the Aβ levels by enhancing endogenous APP proteolysis and decreased nuclear translocation of c-Abl.

[20]

EOC 13.31

EGCG 5 to 20 μM

EGCG suppressed the expression of Aβ-induced TNFα, IL-1β, IL-6, and iNOS, and restored the levels of intracellular antioxidants Nrf2 and HO-1.

[23]

SweAPP N2a

GTE

EGCG reduced the Aβ generation and activated nonamyloidogenic processing of APP by promoting its α-secretase cleavage.

[24]

Div8

EGCG 12.5–50 μM

EGCG induced an increase in the key autophagy adaptor proteins NDP52 and p62.

[27]

M146 L, CHO

EGCG 16–32 μmol/L

EGCG reduced the accumulation of β-amyloid (Aβ).

[28]

N2a/APP695

EGCG (5–100 μM)

EGCG suppressed the production of Aβ and reduced inflammation, oxidative stress and cell apoptosis.

[29]